Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Summary

A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• MASH - Metabolic Dysfunction-Associated Steatohepatitis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Madrigal Pharmaceuticals, Inc.

Last updated on ClinicalTrials.gov

August 26, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites